CIK治疗晚期肾癌患者免疫功能变化与血清胆固醇的相关性研究  

Effect of CIK Cells Immunotherapy on Immunological Function of Patients with Advanced Renal Carcinoma

作　　者：吴昂[1] 朱建伟[1] 高云芬[1] 

机构地区：[1]杭州市肿瘤医院,浙江杭州310002

出　　处：《肿瘤学杂志》2016年第11期942-945,共4页Journal of Chinese Oncology

摘　　要：[目的]观察CIK细胞免疫治疗对晚期肾癌患者免疫功能的影响,分析淋巴细胞亚群与血清胆固醇的相关性。[方法]选取晚期肾癌患者36例,其中20例在常规治疗措施的基础上联合应用CIK细胞免疫方法进行治疗,16例为常规治疗,监测两组患者外周血中总T细胞(CD3^+)、总B细胞(CD3-CD19^+)、NK细胞(CD3^-CD16^+CD56^+)辅助诱导T细胞(CD3^+CD4^+)、CD4/CD8比值等免疫功能指标,并进行统计学分析。[结果 ]联合CIK治疗的肾癌患者外周血中抑制/细胞毒性T细胞从24.41%±8.61%上升到44.41%±19.29%、辅助/诱导T细胞从41.09%±11.52%下降为30.15%±13.96%、CD4/CD8比值从1.95±0.95下降到0.93±0.67、CD3^+HLA-DR^+细胞从15.31%±10.40%上升为45.77%±31.94%、CD8^+HLA-DR^+细胞从10.07%±6.93%上升到36.12%±25.89%,与常规治疗组相比有统计学差异。NK细胞比率与血清总胆固醇、低密度脂蛋白和载脂蛋白B成负相关(r=-0.450,P=0.014;r=-0.469,P=0.010;r=-0.406,P=0.029)。[结论]采用CIK细胞免疫治疗能有效提高转移性肾癌患者的细胞免疫功能,血清胆固醇代谢可能参与调节肿瘤免疫。[Objective] To investigate the immune functions of cytokine^-induced killer（CIK） cells immunotherapy on patients with advanced renal cell carcinoma.[Methods] The data of 36 patients with advanced renal cell carcinoma were analyzed retrospectively. 16 patients received symptomatic treatment,and 20 patients received CIK treatment and symptomatic treatment. Peripheral blood mononuclear cells were isolated from the patients. Flow cytometer was used to detect the CD3~＋T cell,CD3~＋CD4~＋helper T cell,CD3~＋CD8~＋cytotoxic T cell and CD3^-CD16~＋CD56~＋natural killer cells. The changes of lymphocyte subtypes were evaluated. [Results] In the combined treatment group,the percentages of cytotoxic T cell increased from（24.41% ±8.61%） to（44.41%±19.29%）,helper T cell decreased from（41.09%±11.52%） to（30.15%±13.96%）,and the proportion of CD4~＋/CD8~＋decreased from（1.95±0.95） to（0.93±0.67）. The percentages of CD3~＋HLA^-DR~＋cell and CD8~＋HLA^-DR~＋cell increased from（15.31%±10.40%） to（45.77%±31.94%）,（10.07%±6.93%）to（36.12%±25.89%） respectively（P0.05）. The proportion of NK cells were negatively correlated with both the serum total cholesterol（TC）,low density lipoprotein cholesterol（LDL）levels and apolipoprotein B（apo B） levels（r =-0.450,P =0.014;r =-0.469,P =0.010;r =-0.406,P =0.029）.[Conclusion] CIK treatment should efficiently improve the immunological status in advanced RCC patients. The cholesterol metabolism may be involved in modulating tumor immune.

关 键 词：肾肿瘤 CIK治疗 淋巴细胞亚群 胆固醇 

分 类 号：R737.11[医药卫生—肿瘤]